9. Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby JF, Tricoci P, White HD, Zeiher AM; for the ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and cardiovascular outcomes after acute coronary syndrome. *N Engl J Med* 2018;**379**:2097–2107.
10. Szarek M, White HD, Schwartz GG, Alings M, Bhatt DL, Bittner VA, Chiang CE, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Kimura T, Kiss RG, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Roe MT, Tricoci P, Xavier D, Zeiher AM, Steg PG; ODYSSEY OUTCOMES Committees and Investigators. Alirocumab reduces total nonfatal cardiovascular and fatal events: the ODYSSEY OUTCOMES trial. *J Am Coll Cardiol* 2019;**73**:387–396.
11. Yeang C, Witztum JL, Tsimikas S. 'LDL-C' = LDL-C + Lp(a)-C: implications of achieved ultra-low LDL-C levels in the proprotein convertase subtilisin/kexin type 9 era of potent LDL-C lowering. *Curr Opin Lipidol* 2015;**26**:169–178.
12. Andersen PK, Angst J, Ravn H. Modeling marginal features in studies of recurrent events in the presence of a terminal event. *Lifetime Data Anal* 2019;**25**:681–695.
13. Stukel TA, Glynn RJ, Fisher ES, Sharp SM, Lu-Yao G, Wennberg JE. Standardized rates of recurrent outcomes. *Stat Med* 1994;**13**:1781–1791.
14. Landmesser U, Poller W, Tsimikas S, Most P, Paneni F, Lüscher TF. From traditional pharmacological towards nucleic acid-based therapies for cardiovascular diseases. *Eur Heart J* 2020;doi:10.1093/eurheartj/ehaa229.
15. Kinpara K, Okada H, Yoneyama A, Okubo M, Murase T. Lipoprotein(a)-cholesterol: a significant component of serum cholesterol. *Clin Chim Acta* 2011;**412**:1783–1787.
16. Watts GF, Chan DC, Pang J, Ma L, Ying Q, Aggarwal S, Marcovina SM, Barrett PHR. PCSK9 Inhibition with alirocumab increases the catabolism of lipoprotein(a) particles in statin-treated patients with elevated lipoprotein(a). *Metabolism* 2020;**107**:154221.

Corrigendum

doi:10.1093/eurheartj/ehz826
Online publish-ahead-of-print 14 November 2019

Corrigendum to: 2019 ESC/EAS Guidelines for the management of dyslipidaemias: *lipid modification to reduce cardiovascular risk* [*Eur Heart J* (2019); doi:10.1093/eurheartj/ehz455].

The following post-publication corrections have been made to these Guidelines:

In row 4 of Table 3, 'should' has been corrected to 'may';
in 4.2.1, paragraph 3, 'should' has been corrected to 'may' to read 'Overall, CAC score assessment with CT may be considered in individuals. . .' This has also been corrected in the second row of 'Recommendations for cardiovascular imaging for risk assessment of atherosclerotic cardiovascular disease,' and the Class has been corrected to 'IIb';
in the second paragraph of 7.5.2, '5-10 mg of monacolin K' has been corrected to '2.5-10 mg';
and in the Key messages section, number 4, 'ApoB may be a better measure of an individual's exposure to atherosclerotic lipoproteins' has been corrected to 'ApoB may be a better measure of an individual's exposure to pro atherogenic lipoproteins'.

© The European Society of Cardiology and the European Atherosclerosis Association 2019. All rights reserved. For permissions please email: journals.permissions@oup.com.